



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Basiliximab

Cat. No.:	HY-108852
CAS No.:	179045-86-4
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation ^[1] .									
IC₅₀ & Target	Interleukin-2 receptor ^[1]									
In Vitro	<p>Basiliximab specifically inhibits T lymphocyte proliferation by binding to the IL-2Rα^[1]. Basiliximab binds only to activated lymphocytes and macrophages/monocytes^[3]. Basiliximab does not affect resting T lymphocytes that do not express IL-2Rα^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
In Vivo	<p>Basiliximab (CHI 621) (0.07 mg/rat; i.v.; once) decreases total placental natural killer cells in reduced uterine perfusion pressure (RUPP) rats^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Timed-pregnant Sprague Dawley (SD) rats, reduced uterine perfusion pressure (RUPP) rat model of placental ischemia^[2]</td> </tr> <tr> <td>Dosage:</td> <td>0.07 mg/rat</td> </tr> <tr> <td>Administration:</td> <td>IV infusion, once</td> </tr> <tr> <td>Result:</td> <td>Decreased total placental natural killer cells. Had no effect to lower MAP or improve pup weight and placental weight.</td> </tr> </table>		Animal Model:	Timed-pregnant Sprague Dawley (SD) rats, reduced uterine perfusion pressure (RUPP) rat model of placental ischemia ^[2]	Dosage:	0.07 mg/rat	Administration:	IV infusion, once	Result:	Decreased total placental natural killer cells. Had no effect to lower MAP or improve pup weight and placental weight.
Animal Model:	Timed-pregnant Sprague Dawley (SD) rats, reduced uterine perfusion pressure (RUPP) rat model of placental ischemia ^[2]									
Dosage:	0.07 mg/rat									
Administration:	IV infusion, once									
Result:	Decreased total placental natural killer cells. Had no effect to lower MAP or improve pup weight and placental weight.									

REFERENCES

- [1]. McKeage K, et al. Basiliximab: a review of its use as induction therapy in renal transplantation. *BioDrugs*. 2010 Feb 1;24(1):55-76.
- [2]. Cunningham M W, et al. The Role of Interleukin-2 (IL-2) in Natural Killer Cell (NK) Activation and Hypertension in a Preclinical Rat Model of Preeclampsia. *The FASEB Journal*, 2018, 32: 911.1-911.1.
- [3]. Chapman TM, et al. Basiliximab: a review of its use as induction therapy in renal transplantation. *Drugs*. 2003;63(24):2803-35.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA